Brief: Entrada Therapeutics Inc On Track To Report Elevate-44-201 Cohort 1 Data In Q2 2026, Cohort 2 Data By End Of Year
17/02/2026 12:27
Feb 17 (Reuters) - Entrada Therapeutics Inc TRDA.O: ENTRADA THERAPEUTICS INC - ON TRACK TO REPORT ELEVATE-44-201 COHORT 1 DATA IN Q2 2026, COHORT 2 DATA BY END OF YEAR ENTRADA THERAPEUTICS INC - INTENDS TO OPEN EXPANSION COHORT LATER THIS YEAR IN ELEVATE-44-201 STUDY Source text: ID:nGNX25yJ7q Further company coverage: TRDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview